Peptides have become one of the most closely watched regulatory questions in healthcare this summer, with a federal advisory committee vote set for July 23-24 that could reshape what’s legally available to prescribers, wellness clinics and patients nationwide.
What are peptides?
Peptides are short chains of amino acids that often serve as signaling molecules for physiological functions in the body, including tissue repair, metabolism and inflammation. Some peptides, like insulin and semaglutide, the active ingredient in Ozempic and Wegovy, are FDA-approved drugs. Others — including BPC-157, TB-500 and a handful of others marketed for injury recovery, weight loss, sleep and anti-aging — have circulated for years through wellness clinics, medical spas and online retailers without ever being FDA-approved or added to the list of substances legally allowed in pharmacy compounding.
That distinction matters because of how compounding law works. Under Section 503A of the Food, Drug and Cosmetic Act, a licensed pharmacy can only compound a drug for an individual patient using a bulk substance if it’s FDA-approved, has a recognized USP monograph, or appears on the FDA’s 503A Bulks List. If a peptide isn’t on that list, pharmacies generally can’t legally compound it — which is exactly the question now in front of regulators.
The upcoming vote
The FDA’s Pharmacy Compounding Advisory Committee meets July 23-24 to decide whether seven peptides should be added to the 503A bulks list: BPC-157, KPV, TB-500 and MOTs-C, Emideltide (also called DSIP), Semax and Epitalon. The committee’s recommendation is non-binding, but the FDA has historically followed it.
This isn’t the first time these substances have come up for review. The FDA moved more than a dozen peptides, including these seven, into a restricted “Category 2” designation in 2023 that effectively banned their use in compounding, citing safety and evidence concerns.
That changed this spring. After the companies that originally nominated the substances for restriction withdrew their nominations, FDA removed the substances from Category 2 in April, clearing the procedural path for this month’s review.
Public comments on the meeting close July 22, and comments submitted by July 9 will go directly to the committee.
What to watch
1. The panel doesn’t look like past panels. Eight of the committee’s 12 voting members run private wellness, longevity or regenerative medicine clinics — a marked shift from prior PCAC rosters, which drew heavily from university researchers and federal scientists.
The committee’s December 2024 meeting, by contrast, included voting members from Durham, N.C.-based Duke University, the University of California, Riverside, the NIH’s National Institute of Mental Health, the Uniformed Services University and Boston Children’s Hospital — academic and federal voices that ultimately voted down a string of nominated peptides on weak-evidence grounds.
2. Several current panelists have financial ties to the industry whose products they’re reviewing. One voting member is global chief medical officer at a clinic chain that sells peptide, vitamin and weight-loss injections, and another separately promotes peptides like BPC-157 to social media followers and charges for consultations.
3. FDA’s own staff reviewers are recommending against approval — so far. Briefing documents released ahead of the meeting found the evidence weighs against adding BPC-157 and TB-500 to the bulks list. For BPC-157, reviewed for ulcerative colitis, FDA staff cited a single small, poorly documented trial and no human data for the delivery routes proposed. For TB-500, reviewed for wound healing, staff found zero human studies of any kind. Whether the reshaped panel’s vote will follow that staff guidance, or diverge from it, is the central question going into the meeting.
4. There’s a lot of money riding on the outcome. While the legitimate committee vote plays out, a parallel gray market has grown exponentially. Cryptocurrency inflows to unregulated peptide vendors are on pace to cross a $100 million annual run rate in 2026, up from roughly $1 million per quarter in 2024. Some Chinese chemical manufacturers that once supplied fentanyl and amphetamine precursors to drug cartels have shifted into selling unregulated weight-loss and cosmetic peptides directly to U.S. consumers, drawn by a less-regulated, more profitable market that doesn’t reliably screen buyers.
That growth is unfolding entirely outside the legitimate pharmaceutical supply chain the PCAC vote governs, meaning, even a favorable committee outcome isn’t positioned to compete with a gray market that’s already scaling up many times faster.
5. HHS Secretary Robert F. Kennedy Jr. has signaled personal enthusiasm for the category. Mr. Kennedy told podcast host Joe Rogan he is “a big fan of peptides,” and has also reshaped other federal advisory bodies this year. This included firing all 17 members of the CDC’s Advisory Committee on Immunization Practices in June and appointing new members, several with histories of anti-vaccine rhetoric — a pattern some observers see as part of a broader effort to remake the composition of advisory panels across HHS.
What it means for healthcare leaders
For hospital and health system pharmacy leaders, the outcome carries a few concrete implications regardless of which way the vote goes:
- Formulary and compounding policy pressure. If any of the seven peptides land on the 503A list, health system pharmacies may face patient and prescriber demand to add them to compounding formularies — with the underlying safety and efficacy evidence still thin, by FDA staff’s own assessment.
- Competitive pressure from outside traditional care settings. Much of the demand for these substances originates from wellness clinics, medical spas and telehealth platforms operating outside the health system space — a dynamic similar to what’s already played out with compounded GLP-1s, where telehealth firms and compounding pharmacies stepped into the market during branded drug shortages and continued selling compounded versions even after the FDA declared those shortages resolved, prompting an ongoing crackdown and legal battles with manufacturers.
- A slower timeline than the headlines suggest. Even a favorable panel vote doesn’t mean immediate access. Formal rulemaking takes time, giving health systems a longer runway to develop clinical and formulary policy before broader compounding access, if it comes, actually takes effect.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
